Hidehito HORINOUCHI· @HHorinouchi · X·· 1 天前评分70
正文 · 机器翻译
🔥SAFFRON：Osimertinib + savolitinib vs platinum-pemetrexed用于EGFR突变型NSCLC患者在osimertinib治疗后出现MET过表达/扩增
🆙 @NEJM #ESMO26
☑3期RCT；N=338；12个月PFS为36% vs 10%（HR 0.55，p<0.001）；12个月OS为70% vs 53%（HR 0.68，p=0.01）
🎙Shun Lu博士 @nicogirardcurie
#LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders
https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
89 浏览 · 1 赞 · 1 转发 · 0 回复
🆙#ESMO26 Presidential Symposium II: #LCSM 🔥SAFFRON: Osimertinib (Osi) + Savolitinib (Savo) vs Platinum–Pemetrexed (Plat–Pem) in EGFRm MET-Overexpressed (OE) and/or -Amplified (AMP) Advanced NSCLC Post-Osi: Phase (Ph) 3 Primary Results 🎙️Dr. Shun Lu 🔢LBA6 🎯Significantly Improved BICR-PFS (7.6 vs 5.4mo, HR 0.55; n=338) and OS (17.8 vs 12.9mo, HR 0.68, p=0.010) 🎯Grade≥3 TEAEs 64% vs 63%; Discontinuation 14% vs 8% ☑️NCT05261399 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com